OBJECTIVE: To analyze the factors affecting the treatment outcome in patients with presumed ocular tuberculosis on anti-tubercular therapy (ATT). METHODS: Retrospective chart review of patients with presumed ocular tuberculosis seen at a tertiary referral eye care center in the United Kingdom. Failure was defined as recurrence of inflammation within 6 months of completion of ATT. RESULTS: There were a total of 175 patients with presumed ocular tuberculosis who had ATT. Patients with intermediate uveitis or panuveitis and those on immunosuppressive therapy had higher odds of treatment failure (p < 0.05) while those with more than 9 months of ATT (77, 79.38%) had less likelihood of failure. CONCLUSION: We present the largest case series of patients with presumed ocular tuberculosis in a low endemic area treated with ATT. Longer duration of treatment resulted in reduced risk of recurrence of inflammation, whereas immunosuppression adversely affected the final treatment outcome.
OBJECTIVE: To analyze the factors affecting the treatment outcome in patients with presumed ocular tuberculosis on anti-tubercular therapy (ATT). METHODS: Retrospective chart review of patients with presumed ocular tuberculosis seen at a tertiary referral eye care center in the United Kingdom. Failure was defined as recurrence of inflammation within 6 months of completion of ATT. RESULTS: There were a total of 175 patients with presumed ocular tuberculosis who had ATT. Patients with intermediate uveitis or panuveitis and those on immunosuppressive therapy had higher odds of treatment failure (p < 0.05) while those with more than 9 months of ATT (77, 79.38%) had less likelihood of failure. CONCLUSION: We present the largest case series of patients with presumed ocular tuberculosis in a low endemic area treated with ATT. Longer duration of treatment resulted in reduced risk of recurrence of inflammation, whereas immunosuppression adversely affected the final treatment outcome.
Entities:
Keywords:
Anti-tubercular therapy (ATT); QuantiFERON gold in tube (QFT); duration of ATT; immunosuppression; intermediate uveitis; presumed ocular tuberculosis
Authors: Luis Anibarro; Eliana Cortés; Ana Chouza; Alberto Parafita-Fernández; Juan Carlos García; Alberto Pena; Carlos Fernández-Cid; África González-Fernández Journal: Infection Date: 2018-06-04 Impact factor: 3.553
Authors: Erika Marie Damato; Sarah Dawson; Xiaoxuan Liu; Chandoshi Mukherjee; John Horsburgh; Alastair K Denniston; Edward Moran; Martin Dedicoat; Philip Ian Murray Journal: J Ophthalmic Inflamm Infect Date: 2017-12-04